Type I Interferon Signature in Chilblains Following SARS-CoV-2 mRNA Vaccine: A Case Report

Código QR

Type I Interferon Signature in Chilblains Following SARS-CoV-2 mRNA Vaccine: A Case Report

Abstract is missing (Short communication)

Guardado en:

Detalles Bibliográficos
Autores principales:	Karim Souaid, Bénédicte Oulès, Pierre Sohier, Lydia Deschamps, Sélim Aractingi, Nicolas Dupin
Formato:	article
Lenguaje:	EN
Publicado:	Society for Publication of Acta Dermato-Venereologica 2021
Materias:	chilblains COVID-19 SARS-CoV-2 spike protein COVID-19 mRNA vaccine IFN Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/26d43e0190134dcc90f3bf333d84e8b6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
por: Rana Shibli, et al.
Publicado: (2021)

Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
por: Minghui Li, et al.
Publicado: (2021)

Pityriasis Rosea Shortly After mRNA-1273 COVID-19 Vaccination
por: Sun Hye Shin, et al.
Publicado: (2022)

Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
por: Alborz Rahmani, et al.
Publicado: (2021)

Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
por: Serge Goldman, et al.
Publicado: (2021)

Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model
por: Fatima Amanat, et al.
Publicado: (2021)

Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
por: Krzysztof Lukaszuk, et al.
Publicado: (2021)

Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases
por: Dana Elkhalifa, et al.
Publicado: (2022)

Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
por: Matteo Nioi, et al.
Publicado: (2021)

Determinants of COVID-19 Vaccine Hesitancy: A Cross-Sectional Study on a Mexican Population Using an Online Questionnaire (COV-AHQ)
por: Juan Luis Delgado-Gallegos, et al.
Publicado: (2021)

The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
por: Bruna Aparecida Souza Machado, et al.
Publicado: (2021)

The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
por: Pedro Morais, et al.
Publicado: (2021)

Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
por: Ilaria Vicenti, et al.
Publicado: (2021)

Safety and Cross-Variant Immunogenicity of a Three-dose COVID-19 mRNA Vaccine Regimen in Kidney Transplant Recipients
por: Filippo Massa, PhD, et al.
Publicado: (2021)

Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland
por: Piotr Rzymski, et al.
Publicado: (2021)

Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
por: Chin-Shern Lau, et al.
Publicado: (2021)

Dangers of mRNA vaccines
por: Tahoora Ali, et al.
Publicado: (2021)

Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
por: Hamad Ali, et al.
Publicado: (2021)

Lymphadenopathy after the third Covid-19 vaccine
por: Can Özütemiz, et al.
Publicado: (2021)

A Predictive Model for Severe COVID-19 in the Medicare Population: A Tool for Prioritizing Primary and Booster COVID-19 Vaccination
por: Bettina Experton, et al.
Publicado: (2021)

Herpes zoster infection following mRNA COVID-19 vaccine in a patient with ankylosing spondylitis
por: B. Maranini, et al.
Publicado: (2021)

The Waiver of Patent Protections for COVID-19 Vaccines During the Ongoing Pandemic and the Conspiracy Theories: Lights and Shadows of an Issue on the Ground
por: Matteo Nioi, et al.
Publicado: (2021)

Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination
por: Jakub Swadźba, et al.
Publicado: (2021)

Prevalence and Factors Associated with Parents’ Non-Intention to Vaccinate Their Children and Adolescents against COVID-19 in Latin America and the Caribbean
por: Diego Urrunaga-Pastor, et al.
Publicado: (2021)

COVID-19 Vaccine Acceptance among Liver Transplant Recipients
por: Andrea Costantino, et al.
Publicado: (2021)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
por: Davide Ferrari, et al.
Publicado: (2021)

Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe
por: Arkadiusz Dziedzic, et al.
Publicado: (2021)

Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study
por: Shepherd R. Singer, M.D., et al.
Publicado: (2021)

Anti-COVID Vaccination for Adolescents: A Survey on Determinants of Vaccine Parental Hesitancy
por: Stefano Zona, et al.
Publicado: (2021)

Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines—A Case Series
por: Christian Girbardt, et al.
Publicado: (2021)

The Effect of the COVID-19 Vaccine on Daily Cases and Deaths Based on Global Vaccine Data
por: Zhiwei Li, et al.
Publicado: (2021)

The role of COVID‐19 survivor status and gender towards neutralizing antibody titers 1, 2, 3 months after Sinovac vaccine administration on clinical‐year medical students in Indonesia
por: Rivaldo Steven Heriyanto, et al.
Publicado: (2021)

COVID-19: an updated review
por: F. A. Isihak, et al.
Publicado: (2020)

Cutaneous reaction reported after third Moderna COVID-19 vaccine
por: Sophie H. Guénin, MSc, et al.
Publicado: (2021)

COVID-19 reinfection: the role of natural immunity, vaccines, and variants
por: Bao Y. Sciscent, et al.
Publicado: (2021)

Fast and Flexible mRNA Vaccine Manufacturing as a Solution to Pandemic Situations by Adopting Chemical Engineering Good Practice—Continuous Autonomous Operation in Stainless Steel Equipment Concepts
por: Axel Schmidt, et al.
Publicado: (2021)

Recommending COVID-19 Vaccines to Patients: Practice and Concerns of Frontline Family Doctors
por: Paul Kwok Ming Poon, et al.
Publicado: (2021)

Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients – the Vienna Cohort
por: Georg Beilhack, et al.
Publicado: (2021)

Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review
por: David Tak Wai Lui, et al.
Publicado: (2021)

Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12–18 Years in Saudi Arabia
por: Edrous Alamer, et al.
Publicado: (2021)